GLAND PHARMA NEWS
Stock market update: Nifty Pharma index advances 0.11% in a weak market
The Nifty Pharma index was trading 0.11 per cent up at 19780.3.
Stock market update: Nifty Pharma index advances 0.14%
The Nifty Pharma index closed 0.14 per cent up at 19758.25.
Stock market update: Nifty Pharma index advances 1.37% in an upbeat market
The Nifty Pharma index was trading 1.37 per cent up at 19782.05.
Stock market update: Nifty Pharma index falls 0.16%
The Nifty Pharma index closed 0.16 per cent down at 19514.8.
Stock market update: Nifty Pharma index falls 0.08% in an upbeat market
The Nifty Pharma index was trading 0.08 per cent down at 19529.2.
Stock market update: Nifty Pharma index advances 0.07%
The Nifty Pharma index closed 0.07 per cent up at 19545.35.
- Go To Page 1
Stock market update: Nifty Pharma index advances 0.1% in an upbeat market
The Nifty Pharma index was trading 0.1 per cent up at 19541.55.
Stock market update: Nifty Pharma index falls 0.04%
The Nifty Pharma index closed 0.04 per cent down at 19521.15.
Stock market update: Nifty Pharma index falls 0.08%
The Nifty Pharma index closed 0.08 per cent down at 19528.4.
Stock market update: Nifty Pharma index advances 0.61% in an upbeat market
The Nifty Pharma index was trading 0.61 per cent up at 19664.55.
Record block deals! Dalal Street scores Rs 23,000 crore screamer, from a Voda assist
Indian stock markets hit a milestone with record block deals worth ₹23,000 crore, driven by Vodafone Group's stake sale in Indus Towers.
Delta Corp shares surge 15% on GST cut hopes
Shares of Delta Corp, the sole listed company in India's casino gaming industry, saw a significant surge of nearly 15%. This increase in stock price came amidst expectations that the Goods and Services Tax (GST) Council might review the tax structure applicable to online gaming in its upcoming meeting scheduled for June 22.
Stock market update: Nifty Pharma index falls 0.53% in a weak market
The Nifty Pharma index was trading 0.53 per cent down at 19721.95.
Stocks in news: Paytm, Indus Towers, Vedanta, Cipla, Gland Pharma
Domestic markets start positively with Paytm, Indus Towers, Vedanta, Cipla, Gland Pharma in focus. ZEE appoints acting CFO. Tata Technologies partners with Microsoft. Wabco to sell ZF equity. Craftsman Automation launches QIP. Fosun Pharma reduces stake. Vedanta monetises steel business. Goldman Sachs sells One 97 shares; Vodafone sells Indus Towers shares; Generative AI hackathon.
Fosun is said to plan block deals to pare stake in Gland Pharma
The listed arm of billionaire Guo Guangchang’s Fosun International Ltd. holds about 58% of Gland Pharma, which has a market value 303 billion rupees ($3.6 billion). It will carry out more block sales in the coming months to shore up its balance sheet unless buyout firms make an offer, the people said.
Gland Pharma, Hindustan Copper among 18 stocks exited by 7 mutual funds in May
Around seven mutual funds exited from 18 stocks in their portfolio in May. Here is the breakdown of the stocks exited, according to Mutual Fund Insight by Nuvama Alternative & Quantitative Research.
7 mutual funds made complete exit from these midcap stocks
Mutual funds buy and sell stocks and manage their portfolios actively to offer better returns. Here are the midcap stocks which were expelled from 7 mutual funds’ portfolios in May, according to Mutual Fund Insight by Nuvama Alternative & Quantitative Research.
Stock market update: Nifty Pharma index advances 0.5%
The Nifty Pharma index closed 0.5 per cent up at 19838.5.
Stocks in news: ITC, IndiGo, Grasim, Power Grid, Nykaa, Gland Pharma
Grasim Ltd, part of the Aditya Birla Group, reported 39% growth in its consolidated net profit (excluding exceptional item) at Rs 1,908 crore for the quarter ended March 2024.
Stocks in news: Apollo Tyres, Protean e-Gov Tech, Sun Pharma, Nykaa, Paytm
Warburg Pincus arm White Iris Investment will likely offload 3.5% stake in Apollo Tyres through block deals, according to reports.
SAIL, IRCTC among top 10 mid cap stocks that mutual funds bought in April
Mutual funds actively buy and sell securities to manage portfolios and deliver superior returns. Here is the list of the top 10 midcap stocks bought by mutual funds in April, according to a report by ICICI Direct Research.
What HDFC Mid Cap Opportunities mutual fund bought & sold in Jan-Mar quarter
HDFC Mid-Cap Opportunities Fund's transactions in 20 stocks during January-March quarter included buying shares in Ipca Laboratories, Max Financial Services, and Adani Group owned ACC. It also added shares in Timken India, Mahindra & Mahindra Financial Services, and Fortis Healthcare Ltd.
Unstoppable bull run! Sensex scales Mt 75K, Nifty above 22,750 for first time
In a strong start to Tuesday's trading, Indian markets reached new highs despite a subdued performance by US markets the day before. The S&P BSE Sensex crossed the 75,000 milestone, hitting a record high of 75,124, while the Nifty50 also achieved a fresh peak of 22,765.
Gland Pharma shares fall 6% as ex-promoter likely sells stake in block deals
Shares of Gland Pharma dropped 6% to Rs 1,745 on BSE as entities related to ex-promoter Dr Ravi Penmetsa sold 5.5% equity. Large block deals of 91 lakh shares worth Rs 1,600 crore reported.
Stocks in news: Gland Pharma, Axis Bank, Tata Motors, UCO Bank, Jana SFB
Two entities – Nicomac Machinery and RP Advisory Services – are likely to sell upto 4.4% stake in Gland Pharma through block deals on Tuesday, according to news reports.
Two entities likely to sell 4.4% stake in Gland Pharma via block deals: Report
Nicomac Machinery and RP Advisory Services are looking at raising Rs 1,400 crore through the sale, and have set the floor price for the same at Rs 1,725/share. The floor price is at a discount of over 7% to the current market price of the stock. On Monday, shares of Gland Pharma ended nearly 6% higher on the NSE at Rs 1,856.
Stocks in news: Nestle India, Titan, Vodafone Idea, Wipro, Tata Steel
The Board of Nestle India approved paying a royalty fee to its parent company Nestle S.A. The payment will be made at a rate of up to 5.25% of total net sales and it is payable in a staggered manner over five years.
Buy Gland Pharma, target price Rs 2240: Motilal Oswal
Gland Pharma Ltd. key Products/Revenue Segments include Pharmaceuticals, Sale of services, Other Operating Revenue and Export Incentives for the year ending 31-Mar-2023.
Load More